ARCHIVES

Small Phase II Study Finds New Oral Agent May Slow Progression Of Difficult Cancer

This article is from The Cancer Letter archive.

Vol. 32 No. 4 | April 24, 2009

Download PDF Visit The Full Archive

Related Articles

MDV3100 Improves Survival, Reduces Death Risk by 37%

November 25, 2011

DCPC Advisors Okay New Program Project Grants In Prevention

January 27, 1995

ONS Urges Congress To Back Anti-Tobacco Measures.

July 20, 2001

NCI Remains Exception To NIH Authority Over Scientific Counselors

January 27, 1995

California Weighs Listing Tamoxifen As Carcinogen

October 27, 1995

FDA, CMS Take Second Look at Drugs Given “Accelerated” Approval for Cancer

March 21, 2003